Filtered By:
Condition: Cholesterol
Countries: USA Health
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 171 results found since Jan 2013.
The Projected Impact of Population-Wide Achievement of LDL Cholesterol & lt;70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD
ConclusionA substantial number of recurrent ASCVD events could be averted over 10 years if all US adults with ASCVD achieved, and maintained, an LDL-C<70 mg/dL.
Source: Cardiovascular Drugs and Therapy - October 2, 2021 Category: Cardiology Source Type: research
Understanding the impact of psychosocial working conditions on workers ’ health: we have come a long way, but are we there yet?
This issue of the journal includes a meta-review, ie, a systematic review of systematic reviews, summarizing the published evidence on the associations between exposure to adverse psychosocial working conditions and risk of developing diseases or disorders during the past 20 years (1). Although the authors allowed inclusion of reviews reporting results from cross-sectional studies, the majority of the included reviews were restricted to prospective cohort studies – the gold standard method in psychosocial occupational epidemiology. We commend the authors for their succinct summary of the current knowledge on the topic, e...
Source: Scandinavian Journal of Work, Environment and Health - September 3, 2021 Category: Occupational Health Tags: Editorial Source Type: research
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Cardiovascular health status of taxi/for-hire vehicle drivers in the United States: A systematic review
CONCLUSIONS: Rigorous and high quality research is needed to further investigate rates of cardiovascular health in this population. The complexity of data collection in this group presents challenges to this endeavor. The high prevalence of poor nutrition, limited physical activity, diabetes, and blood pressure across studies indicates an urgent need to address low rates of health care access at a policy level and to design targeted workplace interventions.PMID:34219688 | DOI:10.3233/WOR-213525
Source: Work - July 5, 2021 Category: Occupational Health Authors: Sheena Mirpuri Kathryn Traub Sara Romero Marisol Hernandez Francesca Gany Source Type: research
Genes, Vol. 12, Pages 815: A Genetic Study of Cerebral Atherosclerosis Reveals Novel Associations with NTNG1 and CNOT3
d
Levey
Wingo
Wingo
Cerebral atherosclerosis is a leading cause of stroke and an important contributor to dementia. Yet little is known about its genetic basis. To examine the association of common single nucleotide polymorphisms with cerebral atherosclerosis severity, we conducted a genomewide association study (GWAS) using data collected as part of two community-based cohort studies in the United States, the Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP). Both studies enroll older individuals and exclude participants with signs of dementia at baseline. From our analysis of 1325 particip...
Source: Genes - May 26, 2021 Category: Genetics & Stem Cells Authors: Vattathil Liu Harerimana Lori Gerasimov Beach Reiman De Jager Schneider Bennett Seyfried Levey Wingo Wingo Tags: Article Source Type: research
The Association Between Race and Stroke Prevalence in a Patient Cohort in Mississippi
This study includes those patients designated 'black' or 'African-American' admitted with stroke at the University of Mississippi Medical Center. For clarity, this cohort will be identified in this paper as 'black Americans.'PMID:33633519 | PMC:PMC7883364
Source: Perspectives in Health Information Management - February 26, 2021 Category: Information Technology Authors: Christopher Ashley Shamsi Daneshvari Berry Source Type: research
